SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-109610
Filing Date
2022-04-19
Accepted
2022-04-19 17:29:44
Documents
14
Period of Report
2022-04-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d345620d8k.htm   iXBRL 8-K 52662
2 EX-2.1 d345620dex21.htm EX-2.1 513563
3 EX-99.1 d345620dex991.htm EX-99.1 87604
  Complete submission text file 0001193125-22-109610.txt   940987

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20220418.xsd EX-101.SCH 2882
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20220418_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20220418_pre.xml EX-101.PRE 11725
8 EXTRACTED XBRL INSTANCE DOCUMENT d345620d8k_htm.xml XML 3475
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 22835742
SIC: 2836 Biological Products, (No Diagnostic Substances)